Verastem (VSTM) News Today $7.43 0.00 (0.00%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$7.30 -0.13 (-1.68%) As of 05/2/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period B. Riley Has Pessimistic Outlook of Verastem Q2 EarningsVerastem, Inc. (NASDAQ:VSTM - Free Report) - Analysts at B. Riley dropped their Q2 2025 earnings estimates for Verastem in a report issued on Monday, April 28th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will post earnings of ($0.56) per share for the quarter, downMay 3 at 7:12 AM | marketbeat.comVerastem (VSTM) to Release Earnings on ThursdayVerastem (NASDAQ:VSTM) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-verastem-inc-stock/)May 3 at 3:24 AM | marketbeat.comB. Riley Has Optimistic Outlook of Verastem FY2029 EarningsVerastem, Inc. (NASDAQ:VSTM - Free Report) - Equities research analysts at B. Riley increased their FY2029 EPS estimates for Verastem in a note issued to investors on Monday, April 28th. B. Riley analyst K. Patel now anticipates that the biopharmaceutical company will post earnings per share of $May 2 at 9:24 AM | marketbeat.comVerastem Oncology to Present at Upcoming Investor ConferencesMay 2 at 1:53 AM | finance.yahoo.comB. Riley Issues Negative Forecast for Verastem EarningsMay 2 at 1:49 AM | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC increased its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 948,790 shares of the biopharmaceutical company's stock after buying aApril 28, 2025 | marketbeat.comMarshall Wace LLP Invests $4.10 Million in Verastem, Inc. (NASDAQ:VSTM)Marshall Wace LLP acquired a new stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 793,641 shares of the biopharmaceutical company's stock, valued at approximately $April 27, 2025 | marketbeat.comVerastem Oncology Announces $75 million Private Placement | VSTM Stock NewsApril 25, 2025 | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25, 2025 | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25, 2025 | finance.yahoo.comVerastem Oncology rises on $75M private placementApril 25, 2025 | seekingalpha.comVerastem announces U.S. IND clearance of VS-7375April 25, 2025 | markets.businessinsider.comVerastem, Inc. (NASDAQ:VSTM) Shares Sold by Walleye Capital LLCWalleye Capital LLC cut its stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 35.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 139,281 shares of the biopharmaceutical company's stock after selling 76,84April 24, 2025 | marketbeat.comVerastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer TreatmentApril 23, 2025 | marketwatch.comVerastem Oncology to initiate trial for its targeted cancer therapyApril 23, 2025 | msn.comVerastem (VSTM) Gains FDA Nod for Novel Cancer Drug VS-7375April 23, 2025 | gurufocus.comVerastem (VSTM) Advances VS-7375 for Cancer Treatment with FDA Approval | VSTM Stock NewsApril 23, 2025 | gurufocus.comVerastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, ...April 23, 2025 | gurufocus.comVerastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid TumorsApril 23, 2025 | businesswire.comVerastem Oncology to Report Q1 Earnings: What's in the Cards?April 22, 2025 | finance.yahoo.comVerastem (NASDAQ:VSTM) Rating Lowered to Sell at StockNews.comStockNews.com downgraded Verastem from a "hold" rating to a "sell" rating in a report on Friday.April 20, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Position Trimmed by Kennedy Capital Management LLCKennedy Capital Management LLC lowered its stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) by 89.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 63,050 shares of the biopharmaceutical company's stock after selling 553,720 sApril 18, 2025 | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Buy" by AnalystsShares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have earned an average recommendation of "Buy" from the ten analysts that are covering the company, MarketBeat reports. Ten research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages thatApril 15, 2025 | marketbeat.comMizuho Lowers Verastem (NASDAQ:VSTM) Price Target to $8.00Mizuho lowered their price objective on Verastem from $9.00 to $8.00 and set an "outperform" rating for the company in a research report on Wednesday.April 11, 2025 | marketbeat.comVerastem initiated with a Buy at JefferiesApril 11, 2025 | markets.businessinsider.comVerastem: RAMP-203 Study Could Be Next Big Win For Avutometinib CombinationApril 10, 2025 | seekingalpha.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Recursion Pharmaceuticals (RXRX), Masimo (MASI) and Verastem (VSTM)April 10, 2025 | markets.businessinsider.comVerastem initiated Buy at Jefferies on a potential FDA nod for ovarian cancer therapyApril 10, 2025 | msn.comJefferies Initiates Coverage of Verastem (VSTM) with Buy RecommendationApril 10, 2025 | msn.comVerastem (VSTM) Receives Buy Rating from Jefferies with Promising Outlook | VSTM Stock NewsApril 10, 2025 | gurufocus.comVerastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average - What's Next?Verastem (NASDAQ:VSTM) Shares Cross Above 200-Day Moving Average - Here's WhyApril 10, 2025 | marketbeat.comVerastem price target lowered to $8 from $9 at MizuhoApril 10, 2025 | markets.businessinsider.comVerastem (VSTM) Receives a Buy from Mizuho SecuritiesApril 9, 2025 | markets.businessinsider.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 7, 2025 | gurufocus.comVerastem Oncology Reports Progress in Cancer TreatmentsApril 3, 2025 | tipranks.comVerastem, Inc. (NASDAQ:VSTM) Short Interest UpdateVerastem, Inc. (NASDAQ:VSTM - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 7,320,000 shares, a growth of 22.8% from the February 28th total of 5,960,000 shares. Currently, 16.0% of the shares of the stock are sold short. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is presently 5.5 days.April 2, 2025 | marketbeat.comAIGH Capital Management LLC Purchases Shares of 2,665,043 Verastem, Inc. (NASDAQ:VSTM)AIGH Capital Management LLC acquired a new position in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,665,043 shares of the biopharmaceutical company's stock,March 31, 2025 | marketbeat.comResearch Analysts Offer Predictions for Verastem Q1 EarningsVerastem, Inc. (NASDAQ:VSTM - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Verastem in a research note issued to investors on Monday, March 24th. HC Wainwright analyst S. Lee anticipates that the biopharmaceutical company will post earnings of ($0March 28, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Upgraded to "Hold" at StockNews.comStockNews.com raised Verastem from a "sell" rating to a "hold" rating in a research note on Monday.March 25, 2025 | marketbeat.comVerastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025March 25, 2025 | businesswire.comVerastem (NASDAQ:VSTM) Price Target Raised to $14.00Guggenheim increased their price objective on Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a report on Monday.March 25, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Given New $10.00 Price Target at HC WainwrightHC Wainwright raised their price target on shares of Verastem from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday.March 25, 2025 | marketbeat.comVerastem price target raised to $14 from $13 at GuggenheimMarch 24, 2025 | markets.businessinsider.comVerastem CFO Daniel Calkins sells shares worth $630March 24, 2025 | investing.comVerastem price target raised to $10 from $7 at H.C. WainwrightMarch 24, 2025 | markets.businessinsider.comVerastem’s Promising Financial Outlook and Strategic Advancements Drive Buy RatingMarch 24, 2025 | tipranks.comRosalind Advisors Inc. Takes Position in Verastem, Inc. (NASDAQ:VSTM)Rosalind Advisors Inc. purchased a new stake in Verastem, Inc. (NASDAQ:VSTM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 900,000 shares of the biopharmaceutical company's stock, valued at approximatMarch 23, 2025 | marketbeat.comAlliance Global Partners Remains a Buy on Verastem (VSTM)March 22, 2025 | markets.businessinsider.comRoyal Bank of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock PriceRoyal Bank of Canada dropped their price target on shares of Verastem from $16.00 to $14.00 and set an "outperform" rating for the company in a research note on Friday.March 22, 2025 | marketbeat.comBTIG Sticks to Its Buy Rating for Verastem (VSTM)March 21, 2025 | markets.businessinsider.com Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Media Mentions By Week VSTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼0.370.58▲Average Medical News Sentiment VSTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼134▲VSTM Articles Average Week Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MannKind News Celldex Therapeutics News Dynavax Technologies News Innoviva News Novavax News OPKO Health News Geron News Myriad Genetics News Zenas Biopharma News Rigel Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VSTM Stock Free VSTM Stock Alerts